A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients with Cystic Fibrosis who are Homozygous for the F508del-CFTR Mutation and Being Treated with lumacaftor/ivacaftor (ORKAMBI)

Grants and Contracts Details

StatusFinished
Effective start/end date9/30/158/30/17

Funding

  • Nivalis Therapeutics Incorporated: $44,539.00